In-depth structural characterization of Kadcyla® (ado-trastuzumab emtansine) and its biosimilar candidate

The biopharmaceutical industry has become increasingly focused on developing biosimilars as less expensive therapeutic products. As a consequence, the regulatory approval of 2 antibody-drug conjugates (ADCs), Kadcyla® and Adcetris® has led to the development of biosimilar versions by companies locat...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:MAbs
Main Authors: Chen, Liuxi, Wang, Lan, Shion, Henry, Yu, Chuanfei, Yu, Ying Qing, Zhu, Lei, Li, Meng, Chen, Weibin, Gao, Kai
Format: Artigo
Jezik:Inglês
Izdano: Taylor & Francis 2016
Teme:
Report
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5058630/
https://ncbi.nlm.nih.gov/pubmed/27380163
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2016.1204502
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki